Drugs in ATC Class A12C

Up to Top Level ATC Classes

Up to A - Alimentary tract and metabolism

Up to A12 - MINERAL SUPPLEMENTS

Subclasses in ATC: A12C - OTHER MINERAL SUPPLEMENTS

A12CA - Sodium

A12CB - Zinc

A12CC - Magnesium

A12CD - Fluoride

Last updated: July 30, 2026

Market dynamics and patent landscape for ATC class A12C (other mineral supplements)

ATC A12C (“other mineral supplements”) spans heterogeneous products, not a single drug with a unified Orange Book or patent estate. The market dynamics are driven by (1) commodity-like pricing for many mineral salts, (2) switching costs shaped by dose form and dosing frequency, (3) regulatory constraints for line extensions and new formulations, and (4) patent differentiation primarily via formulations (chelated/mineral delivery), manufacturing/process claims, and narrow method-of-use claims for specific deficiencies, populations, or therapeutic contexts. For companies building or licensing IP in A12C, the practical target is formulation and delivery technology rather than “active ingredient” claims, because mineral salts are largely off-patent and frequently available as generics or OTCs.

What does ATC A12C “other mineral supplements” include, and how does that shape the patent landscape?

ATC A12C covers mineral supplements outside the more commonly protected “single mineral” categories. In practice, the group includes products such as:

• Selenium supplements (often selenomethionine or inorganic selenium)
• Iodine/selenium combinations (where iodine is not captured elsewhere in some taxonomies)
• Chromium supplements (commonly chromium picolinate or related chelates)
• Molybdenum supplements
• Boron supplements
• Nickel, vanadium, and other less common minerals sold as dietary supplements
• “Mineral support” blends that use multiple mineral actives at low doses

Because many actives are old, patent value concentrates in:

• Chemical form/chelation (e.g., chelated forms versus inorganic salts)
• Dose form and release profile (extended release, gastroresistant tablets, microencapsulation)
• Stability and bioavailability claims (formulation performance)
• Manufacturing/process claims (specific crystallization, particle size, coating and granulation steps)
• Method-of-use or population-specific claims (pregnancy, dialysis, bariatric surgery, malabsorption states)

Which patent types dominate for mineral supplements?

Patent assets in A12C skew toward:

1. Formulation patents
   • Chelated mineral compositions
   • Fixed combinations (mineral + vitamin, mineral + trace element, or mineral + absorption enhancer)
2. Delivery and manufacturing patents
   • Controlled release matrices
   • Coated pellets or granules
   • Microencapsulation and particle engineering
3. Use patents
   • Treatment or prevention of mineral deficiency in specific populations
   • Use in metabolic indications where mineral depletion is linked to outcomes
4. Process patents
   • How to make chelates or stable intermediates
   • Purification, crystallization, and moisture control methods

How do market dynamics differ between mineral salts, chelates, and controlled-release formulations?

Mineral salts sold as bulk ingredients behave like commodities. Pricing and supply leverage matter more than IP. In contrast, chelates and controlled-release products create differentiation.

Commodity-like segment: inorganic salts and bulk powders

• Low switching barriers when dose equivalence is straightforward
• Limited enforceable IP if the active is off-patent and formulations are simple

Differentiated segment: chelated minerals and proprietary forms

• Better intestinal absorption profiles can support differentiation
• Patents can cover specific chelates, stereochemistry (when applicable), complexes, or stable compositions
• Labeling claims influence payer acceptance and consumer substitution

Higher-moat segment: delivery systems

• Patents often cover release kinetics, coatings, and manufacturing steps
• Clinical relevance can be asserted through bioavailability endpoints
• Counterfeit risk rises if brands rely on consumer trust; stronger IP plus enforcement improves brand defense

Which patents protect A12C minerals: active ingredient vs formulation vs method-of-use?

Featured snippet answer: For most A12C minerals, active ingredient patents are largely expired; enforceable protection is typically formulation, composition of specific mineral forms, and delivery/manufacturing process patents.

Active ingredient patents

• Commonly expired due to long histories of use
• Newer chemical variants (alternate salts, complexes, chelates) can still be patent-protected in certain niches, but coverage is sporadic across the class

Formulation and composition patents

• Most common category for enforceable “product identity”
• Can include:
  • mineral chelates with specified counter-ions or ligands
  • defined ratios in multi-mineral products
  • stabilized compositions with moisture/oxygen control

Method-of-use patents

• Often narrower and harder to enforce due to:
  • difficulty proving infringement when labeling does not track the claim
  • physician prescribing discretion and consumer supplement usage outside claim scope

How long does exclusivity last for A12C products, and when does patent protection lose exclusivity?

For mineral supplements, exclusivity is usually the sum of:

• Patent life (generally 20 years from earliest priority, subject to prosecution and any adjustments)
• Any regulatory exclusivity (rare for OTC supplements; more relevant for drug approvals, if present)
• Practical exclusivity from formulation, clinical data, and brand reputation

Typical wind-down pattern

• As soon as the key formulation patent expires or is designed around, competition accelerates.
• If only method-of-use patents remain, market entry can proceed with the same formulation while avoiding label/claim overlap.

What to monitor for loss of exclusivity

• Expiry of formulation and delivery patents that define “product performance”
• Expiry of manufacturing/process patents that prevent generic replication
• Orange Book status where drugs exist (not uniform across the ATC class)
• Expiration of combination patents covering fixed-dose blends

What is the Orange Book status of A12C minerals?

A12C is an ATC class used across drugs and supplements, and it does not map 1:1 to the FDA Orange Book. Many products are dietary supplements regulated outside the Orange Book framework. For those that are FDA-approved drugs, Orange Book listings can exist, but coverage is heterogeneous across mineral actives and dosage forms.

Featured snippet answer: Orange Book status varies by specific active and dosage form; many A12C “other mineral supplements” products are not Orange Book-listed because they are marketed as dietary supplements rather than approved drug products.

Practical implication for IP diligence

• Separate “dietary supplement IP” (where patents still exist but Orange Book data may be absent) from “FDA-approved drug IP” (where Orange Book can identify listed patents and expiry)
• For licensing, the enforceable baseline is the patent family itself, not any class-level Orange Book signal

How many patents cover A12C minerals, and which companies hold the most defensible IP?

Coverage is highly active- and formulation-specific. Across the broader mineral supplement space, IP ownership typically clusters among:

• Specialty nutraceutical and supplement companies with branded chelates
• Ingredient suppliers that patent chelation or stabilization technologies
• Pharma-adjacent firms that develop regulated drug formulations for mineral deficiencies

For A12C as a class, there is no single “top holder” list that is stable across all minerals because:

• the class contains multiple unrelated actives
• each active has its own commercial players and patent families
• many patents are small, country-specific, and formulation-limited

How strong is the patent estate for A12C, and what determines enforceability?

Patent strength in A12C is driven by enforceability levers that differ from small-molecule pharma:

Composition-of-matter coverage breadth

• Broad Markush-style chelate coverage can be strong but may be narrowed during prosecution
• Narrow “example-driven” claims can be easy to design around via alternate salts, chelators, or release systems

Manufacturing/process dependency

• Process patents can be powerful if a competitor must replicate specific steps to reach equivalent stability/bioavailability
• Enforceability hinges on available evidence of infringement, including process similarity and discovery access

Method-of-use claim limitations

• Enforcement depends on prescribing and labeling alignment
• If claims require a specific protocol, patient selection, or clinical endpoint, infringement proof becomes harder

Patent life reality in nutraceuticals

• Many mineral patents expire quickly relative to branded product lifetimes
• Companies shift to “next generation” delivery improvements and life-cycle management via reformulation patents

What generic entry risks exist for A12C minerals?

Generic entry risk is high when:

• the competitor can source the same mineral form from commodity suppliers
• the patented portion is limited to simple composition without a unique delivery step
• claims are only method-of-use and the label can be modified

Risk is lower when:

• the product is a patented chelate with proprietary stabilization
• the delivery system requires specific manufacturing controls
• fixed combinations rely on a protected ratio and release design

Design-around patterns seen in the space

• Substitute chelate form (e.g., alternate ligands or counter-ions)
• Shift to different release technology (IR tablets versus ER coated beads)
• Remove combinations that trigger fixed-ratio combination claims
• Reframe use claims via labeling changes

How do A12C formulations compare with A11 and A12 other sub-classes in terms of defensibility?

Mineral categories near A11 (vitamins and minerals, with trace elements) can overlap in ingredients but differ in competitive intensity. A12 “mineral supplements” sub-classes often contain:

• better-defined actives with long commercial histories
• more limited patent opportunities when the composition is mature

Defensibility in adjacent classes is similarly skewed toward:

• delivery systems
• chelate selection
• combination formulations

What patent litigation affects A12C minerals?

A12C litigation is typically less visible than large-molecule pharma disputes and often involves:

• supplement/ingredient IP for chelates, stabilized compositions, and process claims
• counterfeiting or trade-dress issues for branded products
• disputes over manufacturing similarity and trade secrets rather than only patent infringement

Public, widely cited patent suits are not uniform across all minerals. Where litigation exists, it tends to be family-specific, with results depending on:

• claim construction of chelate definitions and ranges
• evidence of manufacturing or product composition
• ability to design around with alternative mineral forms

What licensing and settlement dynamics govern A12C mineral deals?

Licensing patterns in mineral supplements track the practical bottlenecks:

• Access to patented ingredient forms (chelate or stabilized complex)
• Access to patented delivery technologies (coatings, encapsulation, granulation and release profiles)
• Rights to use patented clinical or formulation data where relevant

Settlements often focus on:

• product scope boundaries tied to formulation composition and release technology
• time-limited royalty structures during winding-down of key patents
• geographic limitations and duration of “authorized generic” style supply arrangements

Which FDA pathways are relevant to A12C minerals: drug approvals or dietary supplement regulation?

Most A12C “other mineral supplements” marketed to consumers are dietary supplements. That environment changes the regulatory/patent interplay:

• Dietary supplements do not use Orange Book exclusivity constructs.
• For FDA-approved drugs, however, exclusivity ties to NDA/ANDA review and labeling, and Orange Book listings may exist where the active is in an approved drug product.

Practical market access

• Supplement products face market entry through dietary supplement frameworks and current good manufacturing practice compliance
• Drug products face approvals and NDA/ANDA pathways with more structured exclusivity mechanics

Timelines: When do A12C patents typically expire, and what determines the last generic day?

For mineral supplements, “last generic day” is rarely a clean class-wide metric. The timing is defined by:

• earliest priority dates inside the dominant formulation patent families
• country filing dates (USPTO vs EP vs JP, etc.)
• patent term adjustments or extensions where applicable
• continuation practice and claim amendments that may extend enforceable coverage

Operational timeline model used in diligence

1. Identify dominant family:
   • formulation/delivery composition claims with broad embodiments
2. Map jurisdictions:
   • US for litigation leverage, EP for broad coverage, key manufacturing geographies
3. Determine earliest priority and expected expiration:
   • then overlay whether combination/delivery claims expire later via separate families
4. Track life-cycle reformulation:
   • next-generation delivery patents may preserve market position after first family expiry

Key Takeaways

• ATC A12C is too heterogeneous for a single unified patent estate; defensible IP is usually formulation, chelation form, and delivery/manufacturing rather than mineral “active” matter.
• Market dynamics are dominated by commodity substitutes and consumer/prescriber switching behavior; patents protect differentiation when they control bioavailability, stability, and release.
• Exclusivity in this space is driven by patent expiry of delivery and fixed-ratio combination patents; method-of-use-only coverage is generally weaker against design-around.
• Orange Book status is inconsistent across A12C because many products are dietary supplements outside Orange Book listing.
• Licensing and settlements typically revolve around access to patented ingredient forms and delivery technologies, with product-scope boundaries that enable design-around.

FAQs

1) Which A12C minerals are most likely to be protected by formulation patents?

Chelated and delivery-system products (specific chelates, stabilized complexes, controlled-release minerals) are more likely to have enforceable formulation IP than simple inorganic salts.

2) Can competitors launch a product after A12C formulation patent expiry using a different mineral salt?

Often yes. Competitors can design around by selecting alternate salts/chelate ligands, changing release technology, and avoiding fixed-ratio combination claims.

3) Are method-of-use patents in A12C generally easier or harder to enforce?

Harder. Enforcement depends on labeling and actual use matching the claimed protocol, patient selection, and clinical endpoint wording.

4) Do dietary supplements have Orange Book exclusivity?

No. Dietary supplements are typically not Orange Book-listed, so exclusivity mechanics differ from FDA-approved drug products.

5) What is the highest-leverage due diligence step for A12C IP before licensing?

Map which patent families actually control the differentiated technical attributes (chelate form, stabilization method, release kinetics, and manufacturing steps), then align them to the competitor’s “to-be-made” product.

References

1. World Health Organization. (n.d.). ATC classification system: Anatomical Therapeutic Chemical classification. https://www.whocc.no/atc/
2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/